Join Discovery Life Sciences on the Bridging Biomarker Breakthroughs to Bedsides (B4) Tour, an in-person series spotlighting leading biomarker innovation in precision medicine. This exclusive program brings together leading experts to share practical insights and spark collaboration.
Attendees will discover advanced technologies in genomics, proteomics, molecular pathology, and cell biology, all underpinned by CLIA/CAP-accredited, GCLP-compliant labs, including our Health Institute facility in Kassel, Germany, enabling IVDR-compliant studies across Europe.
This tour offers focused sessions, real-world examples, and networking in key biohubs to accelerate precision medicine programs.
Who Should Attend?
Cambridge, UK Agenda*
Each tour stop will feature new speakers following this format. Check back this summer for the full Boston and San Francisco agendas!
| 11:00AM – 11:30AM | Brunch & Registration |
| 11:30AM – 11:40AM | Opening Remarks Greg Herrema, CEO, Discovery Life Sciences |
| 11:40AM – 12:20PM | Keynote Speaker Oliver Burren, Senior Director of Genome Analytics, AstraZeneca |
| 12:20PM -12:50PM | Expert Session Speaker to be announced soon |
| 12:50PM-1:00PM | Proteogenomic Insights Don Skifter, SVP Scientific Affairs, Discovery Life Sciences |
| 1:00PM – 1:40PM | Lunch |
| 1:40PM – 2:00PM | AI Insights Patrick Frey, VP of Precision Medicine, Mindpeak |
| 2:00PM – 2:10PM | A Four-Year Journey Adapting In-House Testing Under IVDR T. Scott Reid, VP and Global Head of Companion Diagnostics, Discovery Life Sciences |
| 2:10PM – 2:50PM | Panel Discussion Patrick Frey, VP of Precision Medicine, Mindpeak Sarah Holt, VP Translational Sciences, Mosaic TX Sara Busacca Principal Scientist – Translational Science Lead, Artios |
| 2:50PM-2:55PM | Closing Insights Greg Herrema, CEO, Discovery Life Sciences |
| 2:55PM-Onward | Optional Breakout Session: Deep Dive Discussions Don Skifter, T. Scott Reid, Anna Juncker-Jensen, Jon Beck, Tony Lovegrove Discovery Life Sciences |
*Agenda (Subject to Change)
 | Keynote Speaker Oliver is Senior Director of Genome Analytics within the Centre for Genomics Research (CGR) at AstraZeneca, leading a team that integrates large-scale proteomics, genomics, and machine learning to support drug development. Prior to joining AZ, he was Director of Genome Informatics within the Department of Medicine at the University of Cambridge. He holds a PhD from the University of Cambridge and has over 20 years of experience in the field of human genetics and genomics. |
 | Patrick Frey Vice President of Precision Medicine, Mindpeak |
 | Sarah Holt VP Translational Sciences, Mosaic Therapeutics |
 | Sara Busacca Principal Scientist – Translational Science Lead, Artios |
 | Don Skifter Senior Vice President, Scientific Affairs, Discovery Life Sciences Don received his PhD in pharmacology and neuroscience focusing on the molecular and genetic mechanisms of learning and memory at the University of Nebraska Medical Center in 2002. He received his MBA from the University of Nebraska, Omaha in 2001. On the heels of the completion of the human genome project in 2003, following a post-doctoral fellowship in Cambridge, MA, he pursued a career in discovery and commercialization of biomarkers in personalized medicine. Don’s work history includes Commercial, Technical, and Scientific Application Support leadership roles at various life science companies including Invitrogen (now Thermo Fisher Scientific), Sequenom (now Agena Bioscience), Complete Genomics (IPO in 2010, acquired by BGI/MGI), the Broad Institute, and OneOme (a start-up pharmacogenomics spinout of the Mayo Clinic). He currently serves as the Senior Vice President, Scientific Affairs focused on genomics and proteomics at Discovery Life Sciences |
 | T. Scott Reid, PhD, MBA Vice President and Global Head of Companion Diagnostics, Discovery Life Sciences Scott brings 25 years of drug development expertise. With experience at SOPHiA Genetics and NeoGenomics, Scott leads innovative CDx solutions for global clinical trials. |
 | Anna Juncker-Jensen Vice President, Scientific Affairs, Discovery Life Sciences Anna Juncker-Jensen is a talented and highly motivated cancer cell biologist currently serving as the VP of Scientific Affairs at Discovery Life Sciences. Anna has extensive experience in scientific leadership, specializing in immuno-oncology biomarkers and clinical trial design. Previously, Anna held key positions at NantBio as a Senior Scientist and NeoGenomics Laboratories in roles including Director of Scientific Affairs. Anna’s academic background includes a PhD from The Scripps Research Institute and a cand.scient. in Biology from the University of Copenhagen. |
Babraham Research Campus
Cambridge, CB22 3AT
.
.
MassBio
700 Technology Square 5th floor
Cambridge, MA 02139
.
.
Timber & Tide
685 Gateway Boulevard
South San Francisco, CA, 94080
Meet Discovery’s local team members at the Cambridge event.
Tony Lovegrove and Jon Beck will be attending and are happy to connect during the day.
Jon Beck, VP Specialty Lab Services, Discovery Life Sciences – Email Jon
.
.
Tony Lovegrove, Director of Business Development, Discovery Life Sciences – Email Tony
.
.
.
.
For questions related to this event, please contact:
Nadia DeStefano, Marketing Event Manager, Discovery Life Sciences
Nadia.DeStefano@dls.com
